Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib

Publication type:
Journal article
Metadata:
Autoren
  • Thomas Efferth
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000417365100007&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1016/j.phymed.2017.11.003
Externe Identifier
  • Clarivate Analytics Document Solution ID: FP1IK
  • PubMed Identifier: 29174651
ISSN
0944-7113
Zeitschrift
PHYTOMEDICINE
Schlüsselwörter
  • Cancer
  • Natural products
  • Small molecule inhibitors
  • Synergy
Paginierung
58 - 61
Datum der Veröffentlichung
2017
Status
Published
Titel
Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib
Sub types
  • Article
Ausgabe der Zeitschrift
37

Data source: Web of Science (Lite)

Other metadata sources:
Autoren
  • Thomas Efferth
DOI
10.1016/j.phymed.2017.11.003
ISSN
0944-7113
Zeitschrift
Phytomedicine
Sprache
en
Paginierung
58 - 61
Datum der Veröffentlichung
2017
Status
Published
Herausgeber
Elsevier BV
Herausgeber URL
http://dx.doi.org/10.1016/j.phymed.2017.11.003
Datum der Datenerfassung
2018
Titel
Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib
Ausgabe der Zeitschrift
37

Data source: Crossref

Abstract
<h4>Background</h4>The shift from cytotoxic to targeted chemotherapy led to improved treatment outcomes in oncology. Nevertheless, many cancer patients cannot be cured from their disease because of the development of drug resistance and side effects.<h4>Purpose</h4>There is an ongoing quest for novel compounds, which raised not only the interest in natural products but also in novel combination therapy regimens.<h4>Study design</h4>In this review, we report on the inhibition epidermal growth factor receptor (EGFR) by targeted small molecules and their combination with natural products from medicinal plants.<h4>Results</h4>The combination of erlotinib with artesunate leads to synergistic inhibition of cell growth in isobologram analyses. Artesunate is an approved anti-malaria drug, which is also active against cancer as shown in vitro, in vivo and in preliminary clinical phase I/II trials.<h4>Conclusion</h4>The combination of natural products (e.g. the sesquiterpenoid artesunate) and synthetic compounds (e.g. the small molecule EGFR tyrosine kinase inhibitor erlotinib) may lead to improved clinical success rates in oncology.
Addresses
  • Department of Pharmaceutical Biology, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany. Electronic address: efferth@uni-mainz.de.
Autoren
DOI
10.1016/j.phymed.2017.11.003
eISSN
1618-095X
Externe Identifier
  • PubMed Identifier: 29174651
Open access
false
ISSN
0944-7113
Zeitschrift
Phytomedicine : international journal of phytotherapy and phytopharmacology
Schlüsselwörter
  • Humans
  • Artemisinins
  • Antineoplastic Combined Chemotherapy Protocols
  • Protein Kinase Inhibitors
  • Molecular Targeted Therapy
  • ErbB Receptors
  • Erlotinib Hydrochloride
  • Artesunate
Sprache
eng
Medium
Print-Electronic
Online publication date
2017
Paginierung
58 - 61
Datum der Veröffentlichung
2017
Status
Published
Datum der Datenerfassung
2017
Titel
Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib.
Sub types
  • Review
  • Journal Article
Ausgabe der Zeitschrift
37

Data source: Europe PubMed Central

Abstract
BACKGROUND: The shift from cytotoxic to targeted chemotherapy led to improved treatment outcomes in oncology. Nevertheless, many cancer patients cannot be cured from their disease because of the development of drug resistance and side effects. PURPOSE: There is an ongoing quest for novel compounds, which raised not only the interest in natural products but also in novel combination therapy regimens. STUDY DESIGN: In this review, we report on the inhibition epidermal growth factor receptor (EGFR) by targeted small molecules and their combination with natural products from medicinal plants. RESULTS: The combination of erlotinib with artesunate leads to synergistic inhibition of cell growth in isobologram analyses. Artesunate is an approved anti-malaria drug, which is also active against cancer as shown in vitro, in vivo and in preliminary clinical phase I/II trials. CONCLUSION: The combination of natural products (e.g. the sesquiterpenoid artesunate) and synthetic compounds (e.g. the small molecule EGFR tyrosine kinase inhibitor erlotinib) may lead to improved clinical success rates in oncology.
Date of acceptance
2017
Autoren
  • Thomas Efferth
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/29174651
DOI
10.1016/j.phymed.2017.11.003
eISSN
1618-095X
Zeitschrift
Phytomedicine
Schlüsselwörter
  • Cancer
  • Natural products
  • Small molecule inhibitors
  • Synergy
  • Antineoplastic Combined Chemotherapy Protocols
  • Artemisinins
  • Artesunate
  • ErbB Receptors
  • Erlotinib Hydrochloride
  • Humans
  • Molecular Targeted Therapy
  • Protein Kinase Inhibitors
Sprache
eng
Country
Germany
Paginierung
58 - 61
PII
S0944-7113(17)30164-2
Datum der Veröffentlichung
2017
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2018
Titel
Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib.
Sub types
  • Journal Article
  • Review
Ausgabe der Zeitschrift
37

Data source: PubMed

Beziehungen:
Property of

Tools